Safety Profile of Baricitinib in Rheumatoid Arthritis (Part Three)

We join our Editor-in-Chief, Peter Taylor (University of Oxford, Oxford, UK) to discuss a selection of abstracts presented at ACR 2021 investigating JAK inhibitors in the treatment of rheumatoid arthritis. 

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

In Part 3, we discuss long term JAK inhibitor exposure and in particular the results presented surrounding the JAK1/2, baricitinib, which used data from nine RCT and one long-term extension study. 

The abstract entitled the ‘Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 9.3 Years: An Updated Integrated Safety Analysis’ (Abstract number: 1688)

Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.

Filmed in coverage of virtual ACR Convergence 2021.